Publications by authors named "Dylan G Buss"
Article Synopsis
- The study aimed to assess the safety and effectiveness of mitomycin C (MMC) in preventing canine corneal scarring.
- In vitro experiments were conducted using healthy canine corneas, with methods including toxicity assays and molecular techniques to evaluate MMC's impact on corneal cells.
- The results indicated that a brief treatment with 0.02% MMC was safe and significantly reduced myofibroblast formation, suggesting potential for decreasing corneal scarring, though further in vivo research is needed.
Objective: To determine if hybrid adeno-associated virus serotype 2/5 (AAV5) vector can effectively deliver foreign genes into the equine cornea without causing adverse side effects. The aims of this study were to: (i) evaluate efficacy of AAV5 to deliver therapeutic genes into equine corneal fibroblasts (ECFs) using enhanced green fluorescent protein (EGFP) marker gene, and (ii) establish the safety of AAV5 vector for equine corneal gene therapy.
Material: Primary ECF cultures were harvested from healthy donor equine corneas.
Objective: Mitomycin C (MMC) is used clinically to treat corneal scarring in human patients. We investigated the safety and efficacy of MMC to treat corneal scarring in horses by examining its effects at the early and late stages of disease using an in vitro model.
Procedure: An in vitro model of equine corneal fibroblast (ECF) developed was used.
Objective: To establish an in vitro model for the investigation of equine corneal wound healing. To accomplish this goal, a protocol to isolate and culture equine corneal keratocytes, fibroblasts and myofibroblasts was developed. ANIMAL MATERIAL: Equine corneal buttons were aseptically harvested from healthy research horses undergoing humane euthanasia for reasons unrelated to this study.
View Article and Find Full Text PDF